Poseida Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage company focused on allogeneic cell therapy and genetic medicines, has announced its participation in two upcoming investor conferences in September 2024. The company will engage in fireside chats at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 10:30am ET and the 2024 Cantor Global Healthcare Conference on September 17 at 1:20pm ET.

These presentations offer investors an opportunity to gain insights into Poseida's progress in developing non-viral treatments for cancer and rare diseases. Live webcasts of both fireside chats will be accessible on Poseida's website, with replays available for approximately 90 days post-presentation.

SAN DIEGO, Aug. 29, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company will participate in fireside chats at the following upcoming investor conferences in September:

H.C. Wainwright 26th Annual Global Investment Conference
Date: Monday, September 9, 2024
Time: 10:30am ET

2024 Cantor Global Healthcare Conference
Date: Tuesday, September 17, 2024
Time: 1:20pm ET

Live webcasts of the fireside chats will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac^® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-upcoming-investor-conferences-302234400.html

SOURCE Poseida Therapeutics, Inc.

FAQ

When is Poseida Therapeutics (PSTX) presenting at the H.C. Wainwright Global Investment Conference in 2024?

Poseida Therapeutics (PSTX) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 10:30am ET.

What is the date and time of Poseida Therapeutics' (PSTX) presentation at the 2024 Cantor Global Healthcare Conference?

Poseida Therapeutics (PSTX) will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 1:20pm ET.

How can investors access Poseida Therapeutics' (PSTX) presentations at the September 2024 conferences?

Investors can access live webcasts of Poseida Therapeutics' (PSTX) fireside chats on the Investors & Media Section of the company's website, www.poseida.com. Replays will be available for about 90 days after the presentations.

What type of treatments is Poseida Therapeutics (PSTX) developing?

Poseida Therapeutics (PSTX) is developing differentiated non-viral treatments for patients with cancer and rare diseases, focusing on allogeneic cell therapy and genetic medicines.